PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of present study was to evaluate the clinical efficacy of hyperbaric oxygen therapy (HBOT) as a primary therapy combined with standard systemic corticosteroid treatment for sudden sensorineural hearing loss (SSNHL) compared to treatment without the use of HBOT (non-HBOT) through clinical data and advanced analytical approaches.
UNASSIGNED: Case-control study.
UNASSIGNED: Conducted across three Japanese medical centers involving 298 SSNHL patients diagnosed between 2020 and 2023. Inclusion criteria encompassed first onset and treatment, WHO grade 3 or 4 initial hearing impairment, receipt of systemic corticosteroid therapy within 14 days of symptom onset, and initiation of HBOT within the same timeframe for the case group. The primary outcome measure was the difference in hearing improvement (mean hearing level in decibels, dB) between the two groups, assessed by pure-tone audiometry at baseline and 3 months post-treatment, using the inverse probability of treatment weighting (IPTW) method adjusted for covariate differences.
UNASSIGNED: The study included 67 patients in the HBOT group and 68 in the non-HBOT group. The HBOT group exhibited significantly greater hearing improvement (IPTW-adjusted difference: 7.6 dB, 95% CI 0.4-14.7; p = 0.038). Patients without vertigo in the HBOT group demonstrated substantial hearing improvement (11.5 dB, 95% CI 2.3-20.6; p = 0.014), whereas those with vertigo showed no significant improvement (-1.8 dB, 95% CI -11.8-8.3; p = 0.729). The HBOT group also had a significantly higher association with complete recovery (IPTW-adjusted odds ratio: 2.57, 95% CI 1.13-5.85; p = 0.025).
UNASSIGNED: In SSHNL, HBOT combination therapy yielded slightly but significantly improved hearing outcomes compared to non-HBOT treatment.
UNASSIGNED: 4.
UNASSIGNED: Case-control study.
UNASSIGNED: Conducted across three Japanese medical centers involving 298 SSNHL patients diagnosed between 2020 and 2023. Inclusion criteria encompassed first onset and treatment, WHO grade 3 or 4 initial hearing impairment, receipt of systemic corticosteroid therapy within 14 days of symptom onset, and initiation of HBOT within the same timeframe for the case group. The primary outcome measure was the difference in hearing improvement (mean hearing level in decibels, dB) between the two groups, assessed by pure-tone audiometry at baseline and 3 months post-treatment, using the inverse probability of treatment weighting (IPTW) method adjusted for covariate differences.
UNASSIGNED: The study included 67 patients in the HBOT group and 68 in the non-HBOT group. The HBOT group exhibited significantly greater hearing improvement (IPTW-adjusted difference: 7.6 dB, 95% CI 0.4-14.7; p = 0.038). Patients without vertigo in the HBOT group demonstrated substantial hearing improvement (11.5 dB, 95% CI 2.3-20.6; p = 0.014), whereas those with vertigo showed no significant improvement (-1.8 dB, 95% CI -11.8-8.3; p = 0.729). The HBOT group also had a significantly higher association with complete recovery (IPTW-adjusted odds ratio: 2.57, 95% CI 1.13-5.85; p = 0.025).
UNASSIGNED: In SSHNL, HBOT combination therapy yielded slightly but significantly improved hearing outcomes compared to non-HBOT treatment.
UNASSIGNED: 4.
摘要：
■本研究的目的是通过临床数据和先进的分析方法，评估高压氧疗法（HBOT）作为与标准全身性皮质类固醇治疗相结合的方法，与不使用HBOT（非HBOT）的治疗相比，对突发性神经性耳聋（SSNHL）的主要治疗方法的临床疗效。
■病例对照研究。
■在三个日本医疗中心进行，涉及298名在2020年至2023年之间诊断的SSNHL患者。纳入标准包括首次发病和治疗，世卫组织3级或4级初始听力障碍，在症状发作后14天内接受全身性皮质类固醇治疗，并在同一时间段内启动病例组的HBOT。主要结果指标是听力改善的差异（平均听力水平以分贝为单位，dB)在两组之间，在基线和治疗后3个月通过纯音测听法评估，使用针对协变量差异进行调整的治疗加权逆概率(IPTW)方法。
■该研究包括HBOT组67例患者和非HBOT组68例患者。HBOT组表现出明显更大的听力改善（IPTW调节差异：7.6dB，95%CI0.4-14.7；p=0.038）。HBOT组没有眩晕的患者表现出显著的听力改善(11.5dB,95%CI2.3-20.6；p=0.014），而那些患有眩晕的患者没有显着改善(-1.8dB，95%CI-11.8-8.3；p=0.729）。HBOT组与完全恢复的相关性也显着较高（IPTW校正比值比：2.57，95％CI1.13-5.85；p=0.025）。
■在SSHNL中，与非HBOT治疗相比，HBOT联合治疗的听力结果略有改善，但显着改善。
■4.
■病例对照研究。
■在三个日本医疗中心进行，涉及298名在2020年至2023年之间诊断的SSNHL患者。纳入标准包括首次发病和治疗，世卫组织3级或4级初始听力障碍，在症状发作后14天内接受全身性皮质类固醇治疗，并在同一时间段内启动病例组的HBOT。主要结果指标是听力改善的差异（平均听力水平以分贝为单位，dB)在两组之间，在基线和治疗后3个月通过纯音测听法评估，使用针对协变量差异进行调整的治疗加权逆概率(IPTW)方法。
■该研究包括HBOT组67例患者和非HBOT组68例患者。HBOT组表现出明显更大的听力改善（IPTW调节差异：7.6dB，95%CI0.4-14.7；p=0.038）。HBOT组没有眩晕的患者表现出显著的听力改善(11.5dB,95%CI2.3-20.6；p=0.014），而那些患有眩晕的患者没有显着改善(-1.8dB，95%CI-11.8-8.3；p=0.729）。HBOT组与完全恢复的相关性也显着较高（IPTW校正比值比：2.57，95％CI1.13-5.85；p=0.025）。
■在SSHNL中，与非HBOT治疗相比，HBOT联合治疗的听力结果略有改善，但显着改善。
■4.
